T-group (topology)

304.31.2 Substrate-binding domain of HMG-CoA reductase

Ligands and drugs

310
Member domains
157
with ligand contacts (≤ 4 Å)
50.6% of members
150
with DrugDomain annotations
48.4% of members
116
with a DrugBank compound
37.4% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

Chemical profiles are computed for X-groups. 304.31.2 belongs to X-group 304 Alpha-beta plaits, which binds 8.8 ligand superclasses per 20 proteins, broader than 75% of the 256 X-groups with enough proteins to compare. View its chemical profile →

DrugBank compounds

DrugBankPDB ligandNameDomains
DB16833ADPAdenosine disphosphate21
DB03461NAPNicotinamide adenine dinucleotide phosphate14
DB03169HMG(S)-Hmg-Coa12
DB01992COACoenzyme A11
DB14128NADNadide9
DB03518MEVMevalonic acid8
DB04377MAHMeglutol8
DB04447DTT1,4-Dithiothreitol5
DB00439116Cerivastatin4
DB01076117Atorvastatin4
DB01095115Fluvastatin4
DB01098FBIRosuvastatin4
DB14714SIMTenivastatin3
DB02338NDPNADPH2
DB00157—NADH1
DB00175——1
DB00227—Lovastatin1
DB00641——1
DB03785LVAMevinolinic acid1
DB06693—Mevastatin1

Most frequently bound compounds

PDB ligandNameDomains in contact
ADPADENOSINE-5'-DIPHOSPHATE22
COACOENZYME A19
NADNICOTINAMIDE-ADENINE-DINUCLEOTIDE17
NAPNADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE14
MEV(R)-MEVALONATE13
HMG3-HYDROXY-3-METHYLGLUTARYL-COENZYME A12
CAmetalCALCIUM ION9
882(3R,5R)-7-[5-(ANILINOCARBONYL)-3,4-BIS(4-FLUOROPHENYL)-1-ISOPROPYL-1H-PYRROL-2-YL]-3,5-DIHYDROXYHEPTANOIC ACID8
MAH3-HYDROXY-3-METHYL-GLUTARIC ACID8
DTT2,3-DIHYDROXY-1,4-DITHIOBUTANE6
114(3R,5R)-3,5-dihydroxy-7-[(1S,2S,8S,8aR)-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid4
115(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid4
1167-[4-(4-FLUORO-PHENYL)-5-HYDROXYMETHYL-2,6-DIISOPROPYL-PYRIDIN-3-YL]-3,5-DIHYDROXY-HEPTANOIC ACID4
1177-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID4
3HI(3R,5R)-7-[2-(4-fluorophenyl)-4-[(2-hydroxyphenyl)carbamoyl]-5-(1-methylethyl)-3-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid4
4HI(3R,5R)-7-[4-(benzylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-imidazol-1-yl]-3,5-dihydroxyheptanoic acid4
5HI(3R,5R)-7-[2-(4-fluorophenyl)-4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}-5-(1-methylethyl)-1H-imidazol-1-yl]-3,5-dihydroxyheptanoic acid4
6HI(3R,5R)-7-{2-[(4-fluorobenzyl)carbamoyl]-4-(4-fluorophenyl)-1-(1-methylethyl)-1H-imidazol-5-yl}-3,5-dihydroxyheptanoic acid4
7HI(3R,5R)-7-[3-(biphenyl-4-ylcarbamoyl)-2-ethyl-5,6,7,8-tetrahydrocyclohepta[b]pyrrol-1(4H)-yl]-3,5-dihydroxyheptanoic acid4
8HI(3R,5R)-7-{3-(4-fluorophenyl)-1-(1-methylethyl)-4-phenyl-5-[(4-sulfamoylphenyl)carbamoyl]-1H-pyrrol-2-yl}-3,5-dihydroxyheptanoic acid4